The Economic Potential of Tamoxifen Prophylaxis in Breast Cancer

This publication has 12 references indexed in Scilit:

• Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial
  JNCI Journal of the National Cancer Institute, 1995
• The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs
  The American Journal of Medicine, 1995
• Systemic Therapy in Breast Cancer
  PharmacoEconomics, 1994
• Breast cancer chemoprevention
  European Journal Of Cancer, 1993
• Breast cancer chemoprevention tamoxifen: Current issues and future prospective
  Cancer, 1993
• Tamoxifen prophylaxis in breast cancer.
  1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
  1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
  1992
• Symptoms Associated With Tamoxifen Treatment in Postmenopausal Women
  Archives of internal medicine (1960), 1991
• Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programme
  European Journal of Cancer and Clinical Oncology, 1990